, 208:257 | Cite as

Exogenous cortisol acutely influences motivated decision making in healthy young men

  • Peter Putman
  • Niki Antypa
  • Panagiota Crysovergi
  • Willem A. J. van der Does
Open Access
Original Investigation



The glucocorticoid (GC) hormone cortisol is the end product of the hypothalamic–pituitary–adrenal axis (HPA axis). Acute psychological stress increases HPA activity and GC release. In humans, chronic disturbances in HPA activity have been observed in affective disorders and in addictive behaviour. Recent research indicates that acute effects of GCs may be anxiolytic and increase reward sensitivity. Furthermore, cortisol acutely influences early cognitive processing of emotional stimuli.


In order to extend such findings to more complex emotional-cognitive behaviour, the present study tested acute effects of 40 mg cortisol on motivated decision making in 30 healthy young men.


Results showed that cortisol indeed increased risky decision making, as predicted. This effect occurred for decisions where making a risky choice could potentially yield a big reward. These results are discussed with respect to currently proposed mechanisms for cortisol’s potential anxiolytic effect and GCs’ involvement in reward systems.


Cortisol HPA axis Emotion Anxiolytic Reward Decision making 


The glucocorticoid hormones (GCs; cortisol in humans) are produced as the end product of the hypothalamic–pituitary–adrenal axis (HPA axis). After a physiologic or psychological stressor, corticotropin-releasing factor (CRF), synthesised in the paraventricular nucleus of the hypothalamus, is released into the anterior pituitary, which responds by increasing its output of adrenocorticotropin hormone (ACTH). ACTH is then released into the bloodstream and stimulates the release of cortisol by the adrenal glands. When central cortisol concentrations are elevated to stress levels, cortisol binds to GC receptors (GRs), whose density is purportedly highest in limbic and prefrontal areas where they probably influence reciprocal prefrontal-limbic circuits of emotion regulation (de Kloet et al. 1999; Sapolsky 2000; de Kloet et al. 2005; Ochsner and Gross 2005; Urry et al. 2006). Because of the involvement of the HPA axis in psychological stress, its relation to psychopathology has been studied extensively. Chronic HPA dysregulation (mainly hypercortisolism) has been reported for mood and anxiety disorders (Yehuda et al. 1996; Yehuda 2001; Young and Breslau 2004; Takahashi et al. 2005; Mantella et al. 2008; Vreeburg et al. 2009). Addictive behaviour is also associated with disturbances of HPA functioning and HPA-induced sensitisation of the dopaminergic (DA) mesolimbic ‘reward’ system (Marinelli and Piazza 2002; Koob and Kreek 2007; Sinha 2008). Acute effects of GCs may also contribute to increased reward-seeking and risk-taking behaviour related to substance abuse and pathological gambling (Marinelli et al. 1998; Mantsch and Katz 2007; Wohl et al. 2008; van den Bos et al. 2009). For stress-related psychopathology, the observed long-term alterations of HPA functioning may be partly due to dysregulation of the HPA negative feedback system as a result of unduly wear and tear on GRs (Yehuda 2004). Much less is known about acute effects of cortisol on emotion regulation and the manifestation of negative affect, sensitivity to punishment and anxiety.

Several recent publications suggest that exogenous GCs may reduce fear and biassed attentional and working-memory processing of threat-related stimuli (Soravia et al. 2006; Het and Wolf 2007; Putman et al. 2007a, b; Oei et al. 2009; Vasa et al. 2009). This may be taken to suggest that cortisol acutely alters cognitive processing (attention, working memory, or memory retrieval) of threat- and withdrawal-related negative arousing information (see Putman et al. 2007a; de Quervain and Margraf 2008). However, it may also be the case that cortisol acutely influences bottom-up affective state, resulting in altered performance on sensitive emotional-cognitive experimental tasks only as a secondary effect. This may not be restricted to anxiolytic-like effects, but cortisol may also promote a more reward-driven or approach-motivated affective state. Animal models indeed suggest that high levels of GCs increase reward- and approach-related behaviour, likely due to increased DA activity (Marinelli et al. 1998; Marinelli and Piazza 2002; Mikics et al. 2007).

Hence, the present study sought to establish if cortisol acutely influences performance on a motivated decision-making task wherein choice behaviour is influenced by sensitivity to cues of punishment and reward. This motivated decision-making task (Rogers et al. 2003) presents subjects with 80 rounds of a gambling game in which they have to choose to play a control gamble with a fixed expectancy value or to play experimental gambles, which vary in their associated potential losses, potential gains and the probability of losing/winning. Choice between playing the control gamble or the experimental gamble is dictated by the perceived attractiveness of the experimental gamble relative to the control gamble and so depends on the attention that subjects pay to these cues of potential punishment and reward and on how they weigh their relative importance. This task has been utilised repeatedly to assess effects of different psychopharmalogical manipulations (e.g. Rogers et al. 2003, 2004; Antypa et al. 2009). Since cortisol may also acutely promote reward-driven behaviour (though there is less empirical support for such a prediction from research in humans), we also tested if cortisol administration would result in increased sensitivity to reward. No effects on self-reported state anxiety were expected (as also reported in, for instance, Buchanan et al. 2001; Abercrombie et al. 2003; Tops et al. 2003; Putman et al. 2007a, b; Oei et al. 2009).



Thirty healthy young men were recruited on campus and were paid for their participation. Exclusion criteria were drug use, habitual smoking, alcoholism, any past or current psychiatric, endocrine or neurological illness and excessive physical exercise. One participant demonstrated abnormal performance on the decision-making task (see below) and only data of the 29 remaining men are reported. Mean (M) age was 22.7 years [range, 20–30 with a standard deviation (SD) of 2.5]. The study was approved by the local review board, and all subjects provided written informed consent.

Design and procedures

Performance on various instruments was measured after subjects were orally administered two different capsules, identical in appearance, containing 40 mg hydrocortisone + 320 mg Primogel or 360 mg Primogel on two separate testing sessions in a double-blind, placebo-controlled crossover design. Order of drug administration was counterbalanced across the subjects with 15 subjects receiving placebo on the first day of testing and 14 subjects receiving cortisol on the first day; (washout ≥ 72 h). Curvilinear dose–response effects of GCs have been reported for some cognitive effects of cortisol. Buchanan et al. (2001) compared effects of 5 and 20 mg cortisol on a psychophysiological fear index and also suggested a nonlinear dose–response with apparent fear-reducing effects after the higher dose. The present dose of 40 mg was chosen as the highest level tested so far in human research for anxiolytic-like effects. In addition, this administration procedure is exactly as in our previous studies (Putman et al. 2007a, b, 2009). Testing was done between 1300 and 2000 hours at the same time on both days. Subjects were required to refrain from intake of any nutrients for at least 1.5 h prior to the start of the lab session. On arrival, they first completed a questionnaire to assess state anxiety (the STAI-s; van der Ploeg et al. 1980; Spielberger 1983) after which the capsule was administered. One hour later, another STAI-s was administered, after which computerised testing began. Participants then performed two experimental tasks designed to assess attentional processing of neutral and emotional pictorial stimuli, some of which may have been stressful to watch (data reported elsewhere). The decision-making task was administered last, approximately 2 h after capsule administration.

Decision-making task

This task contains 80 trials in which subjects have to choose between two gambles with the aim of earning as many game credits as possible. Coloured vertical bars of varying length indicate the probability of winning/losing, and the amount of credits that can be gained/lost is indicated at the top and bottom of the bars. Subjects were told that they would be paid a small amount of money for earned game credits to increase motivation to perform well on the task. Each trial lets the participant choose between a control gamble and an experimental gamble. For all trials other than the wins only and losses only trials (see below), this control gamble predicts a 0.5 probability of winning and a 0.5 probability of losing ten credits. Experimental gambles vary in the probability of losing or winning (0.4 probability of losing versus 0.6 probability of losing), the amount of expected gains (30 versus 70 credits) and the amount of expected losses (30 versus 70 credits), yielding a total of eight trial types that are each presented eight times (see Table 1). In addition, there are eight ‘wins only’ and eight ‘losses only’ trials. Wins only trials present the subjects with a choice between a guaranteed win of 30 credits and a gamble with 0.5 probability of winning 60 credits versus a 0.5 probability of winning nothing. The losses only trials present a choice between a guaranteed loss of 30 credits and a gamble representing a 0.5 probability of losing nothing and 0.5 probability of losing 60 credits. Typically, subjects choose the guaranteed win in wins only trials and gamble on the losses only trials. Order of trial types is randomised within four continuously presented blocks of 20 trials presenting each trial type twice per block. Dependent measures are proportionate choice scores—the number of times the participant chooses a certain experimental gamble relative to the frequency of occurrence of that trial type. For the wins/losses only trials, proportionate scores reflect the number of times the subjects chose the guaranteed win/loss relative to the number of trials of that condition.
Table 1

The eight conditions in the decision-making task where participants have to chose between playing a control gamble or an experimental gamble

Proportionate Choice Trials

Trial number


Expected gains

Expected losses


High (60%)

Large (70)

Large (70)


Small (30)


Small (30)

Large (70)


Small (30)


Low (40%)

Large (70)

Large (70)


Small (30)


Small (30)

Large (70)


Small (30)

The control gamble predicts a 0.5 probability of winning and a 0.5 probability of losing ten credits. Experimental gambles vary in the probability of losing/winning, the amount of expected gains and the amount of expected losses, yielding a total of eight trial types

Data reduction

Data from one participant were discarded; this participant took on average more than 13 s to choose on one of the testing days versus an average of approximately 2 s for the other subjects. Distributions of raw, log-transformed and arc sine-transformed performance scores for the decision-making task all differed significantly from normal, so only non-parametric statistical tests were performed for this experimental task. In order to test interactions between various conditions, contrast scores were calculated by subtracting the number of proportionate choice scores for various trial types. To test the effects of drug on probability of losing, scores for high probability of losing were subtracted from scores for low probability of losing for the two drug conditions separately. To calculate the expected gains contrast score, scores for low expected gains were subtracted from scores for high expected gains. An expected losses contrast score was similarly calculated for high versus low expected losses. Note that for all these contrast scores, larger scores indicate stronger preference for less risky and more rewarding choices.

Within-subject comparisons between the various proportionate choice scores and contrast scores were performed with Wilcoxon rank tests. Between-subject comparisons for the effects of order of administration (either placebo or cortisol on the first day of testing) were performed with Mann–Whitney U tests, but since no relevant comparisons showed an effect of order, these tests are not further mentioned below. State anxiety measures and salivary cortisol concentrations were tested in repeated measures ANOVA’s with drug (2; placebo versus cortisol) and time (2; before and after drug administration) as within subject factors. Initially, order was entered as a between-subject factor, but since order showed no effects, it was removed from the analyses and is not further reported below. Paired-sample t tests were used for simple mean comparisons of cortisol concentrations.



One saliva sample for one participant was lost (the pre-administration sample in the placebo session). A repeated measures ANOVA was performed with drug and time as within-subjects factors and salivary cortisol concentrations as dependent variable. This showed a significant main effect of drug [F(1,27) = 53.96; p < 0.001], a significant main effect of time [F(1,27) = 52.84; p < 0.001], and a significant drug × time interaction [F(1,27) = 55.68; p < 0.001]. The main effects of drug and time are carried by the high cortisol concentration in the post-administration sample in the cortisol condition. In the placebo condition, mean cortisol concentration dropped from 7.73 nmol/L before administration to 3.89 nmol/L after administration, ~1 h later [t(27) = 3.17; p < 0.005]. In the cortisol condition, mean cortisol concentration rose from 6.47 nmol/L before administration to 116.4 nmol/L after administration [t(28) = 7.44; p < 0.001]. Post-administration cortisol concentrations differed significantly between placebo and cortisol conditions [t(28) = 7.50; p < 0.001].

State anxiety

STAI-s data for one participant were removed before analyses because his STAI-s scores were extremely high (>2 SDs above the mean on all measurements). For the remaining subjects, a repeated measures ANOVA with time (before or after drug administration) and drug (placebo or cortisol) as within-subject factors and STAI-s score as dependent variable was performed. This showed no main effect of drug [F(1,27) = 0.063; p > 0.05], no time × drug interaction [F(1,27) = 0.140; p > 0.05], but a borderline significant main effect of time [F(1,27) = 4.185; p < 0.1]. This trend-level main effect reflected a slight drop in STAI-s between the first and second measurement across both drug conditions: from M = 30.9 (SD = 5.4) to M = 29.8 (SD = 5.5).

Gambling task

Median proportionate choice scores are presented in Fig. 1a. Cortisol had no effect on overall frequency of choice for experimental gambles (z = 0.901; p > 0.05). Subjects more often preferred to gamble on the losses only than on the wins only trials (z = 3.977, p < 0.001), but this was not influenced by drug condition (z = 0.299; p > 0.05). More experimental gambles were made for trials with small expected losses than large expected losses (z = 4.5345; p < 0.001). Drug condition had no significant effect on the expected losses contrast score reflecting this risk avoidant choice pattern (z = 0.272; p > 0.05). More experimental gambles were made for trials with large expected gains than for trials with small expected gains (z = 4.628; p < 0.001). The expected gains contrast score reflecting this reward-driven choice pattern was not influenced by drug condition (z = 1.039; p > 0.05). More experimental gambles were made for trials with a low probability of losing than for trials with a high probability of losing (z = 4.705; p < 0.001). Drug condition significantly influenced the probability of losing contrast score (z = 2.106; p < 0.05). Subjects made more high-risk experimental gambles after cortisol than after placebo. To clarify the nature of this effect of drug, low and high probability of losing conditions were analysed separately. Although cortisol had no effect on choice pattern in the low probability of losing condition (z = 0.396; p > 0.05), it significantly increased risk-seeking when the probability of losing was high (z = 1.763; p < 0.05; one tailed). We further explored this effect and analyses of the separate trial types with a high probability of losing showed that cortisol significantly increased the number of experimental gambles of the most risky kind, i.e. when there was a high probability of losing a large amount of credits (z = 2.519; p < 0.025), especially when there was also a large possible gain (z = 2.802; p < 0.005). Since this last test concerns effect of cortisol on but one of eight experimental trial types, it is important to note that it also proves significant when using a Bonferroni-corrected alpha of 0.006 (see Fig. 1b).
Fig. 1

a Median proportionate choice scores and 25th and 75th percentile limits for the eight experimental conditions. b Proportionate choice scores for the high-risk situation where there is a large probability of losing. For wins only and losses only, a higher score indicates fewer participants chose to gamble instead of taking the guaranteed win/loss. For all other measures, a higher score indicates that participants more often chose experimental gambles over than control gambles


Our main hypothesis was that 40 mg of cortisol would acutely decrease punishment-sensitive behaviour on the gambling task. We also thought it was possible that cortisol would increase reward-sensitive behaviour. Results showed that cortisol changed motivated decision-making in a manner compatible with both notions.

Analysis of salivary cortisol samples confirmed that the cortisol manipulation was successful in significantly raising cortisol concentrations to levels very similar to those reported earlier for single oral 40 mg administrations (see, e.g. Abercrombie et al. 2003; Putman et al. 2007a). Results also showed a slight cortisol drop between the first and second salivary samples in the placebo condition, which probably reflects normal diurnal variation and/or habituation to the slight initial stress of coming to the lab for an administration study (cf. Putman et al. 2007a).

As expected, no effect on self-reported anxiety was observed. Only under very stressful circumstances (exposure to phobic stimuli, exposure to a strong laboratory stressor, or yohimbine-induced panic attack; Soravia et al. 2006; Het and Wolf 2007; Vasa et al. 2009) does cortisol seem to influence self-reported affective state. Several studies in healthy participants have reported that administrations of up to 40 mg cortisol does affect performance on more sensitive experimental measures of affect and emotional cognition in the absence of effects on non-challenged self-reported affective state (e.g. Tops et al. 2003, 2006; Putman et al. 2007a, b; Oei et al. 2009). This suggests that cortisol does not work by directly altering affective state but, rather, by altering the cognitive processing of emotional information that people encounter during their ongoing interactions with the environment [see de Quervain and Margraf (2008) for a different instance of such a biological-cognitive hypothesis, which applies specifically to phobic memories and also see Harmer (2008)].

Presently, as expected, cortisol reduced the influence of perceived probability of losing on performance of the gambling task. Although subjects typically shun the gambles with a high probability of losing compared to gambles with a low probability of losing, this risk-avoidant behaviour was reduced by cortisol. Rogers et al. (2004) reported that administration of a beta-adrenergic antagonist had the clearest effect on performance of this task when the probability of losing as well as the amount of potential losses were high, as was presently found. Interestingly, administration of such beta-adrenergic antagonists tends to acutely increase cortisol levels (see, e.g. Kizildere et al. 2003). Closer inspection of the present effect on the compound variable of probability of losing showed that the effect was carried by an increased proportion of risky choices in a single condition where the experimental gamble also offers a large potential gain. This behavioural pattern is probably best understood as reflecting a combined effect of reduced sensitivity to cues of punishment and increased sensitivity to reward.

Only little human research into potential acute effects of cortisol on reward-driven behaviour has been reported. Tops et al. (2006) reported increased approach-motivated locomotor behaviour. Putman et al. (2007b) reported increased selective processing of angry faces after cortisol administration. This was assumed to reflect increased socially agonistic motivational tendencies that have been linked to approach- and reward-driven behaviour (van Honk et al. 2001; d’Alfonso et al. 2000; Putman et al. 2004; Wirth and Schultheiss 2007; Beaver et al. 2008; Hermans et al. 2008; Passamonti et al. 2008; Carver and Harmon-Jones 2009). Most recently, van den Bos et al. (2009) reported cortisol effects on another motivated decision-making task (the Iowa gambling task or IGT; Bechara et al. 1996) in participants who had been subjected to a psychological stressor. The subjects with larger cortisol responses to the stressor demonstrated a performance pattern that reflects perseverance in making decisions that not only yield high immediate reward but also result in more severe punishment. Such a pattern of IGT performance is typical for less anxiously inhibited more reward-oriented participants (e.g. van Honk et al. 2002). Therefore, it is highly likely that the data reported by van den Bos et al. truly reflect effects of neuroendocrine agents involved in the stress response and do not merely result as a psychological response to the stressor. As such, their results showing that higher cortisol levels predict more reward and less punishment sensitivity are very much in line with the present results. Finally, it has also been demonstrated that administration of GCs increases self-administration of psychostimulant drugs in rodents (Marinelli et al. 1998; Mantsch and Katz 2007). A mechanism likely causing such increased reward-seeking behaviour is GCs’ acute increase of DA activity in the nucleus accumbens (NAcc), a vital structure in the mesolimbic DA reward pathway (Marinelli and Piazza 2002).

It seems quite possible then that relations between HPA activity and pathological gambling (Wohl et al. 2008), reward-driven and punishment-insensitive effects as observed by van den Bos et al., as well as the present results, may be mediated by cortisol’s effect on NAcc DA activity. Both the results of van den Bos et al. with the IGT and the present results constitute an effect of cortisol on conditions that simultaneously present a great risk and a great reward cue. These are high arousing situations likely involving simultaneous activation of neuroendocrine stress and reward systems, both of which may be involved in cortisol’s apparent stress-reducing effects. CRF, an important neurohormone in the HPA stress cascade, has been reported to have anxiogenic and depressogenic effects in non-human primates (Strome et al. 2002), so increased negative feedback resulting from our cortisol administration may influence sensitivity to arousing cues of punishment. Cortisol itself may also affect stress directly via stimulation of GRs in limbic-prefrontal emotion regulation circuits (e.g. de Kloet et al. 1999, 2005; Etkin et al. 2006; Liberzon et al. 2007). Alternatively, potentially anxiolytic interactions between cortisol and its metabolites and GABA are possible. (see Putman et al. 2007a). Finally, NAcc DA-stimulating properties of cortisol have been proposed to reduce stress through reward sensitisation (see Marinelli and Piazza 2002). Possibly then, subtle effects of cortisol on the decision-making task may only become observable when both reward and stress systems involved in cortisol’s affective properties are triggered, as also inherent in performance of the IGT. Of course, all this remains speculative, and it is possible that different mechanisms are needed to explain the diversity of abovementioned findings. An alternative to this speculative explanation of the apparent specificity of the observed effect is to interpret it as a mere chance finding in a single condition. However, the effect remains significant after chance-level correction, so the finding is statistically sound and not likely spurious.

Several factors limit the interpretation of this study and its results. Firstly, in order to exclude possibly confounding influences of menstrual endocrine fluctuations and as a replication of several relevant previous studies (e.g. Putman et al. 2007a, b; Oei et al. 2009), only men were tested. These results may not generalise to women. Secondly, only a dose of 40 mg of cortisol was tested. Because the relation between cortisol levels and (cognitive) behaviour may be nonlinear (see e.g. Buchanan et al. 2001; Lupien et al. 1999), future studies may address the issue of dose–response relation.

The potential therapeutic value of GC administration in the treatment of anxiety disorders is an important current issue (Aerni et al. 2004; Soravia et al. 2006; Schelling et al. 2006; de Quervain and Margraf 2008). The present study adds to our knowledge of possible anxiolytic properties of cortisol by being the first to demonstrate that cortisol affects more complex-motivated behaviour in healthy subjects.



Willem van der Does and Peter Putman are both supported by innovative research-grants from the Netherlands Organization for Scientific Research (NWO; numbers 453-06-005 and 451-07-028).

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.


  1. Abercrombie HC, Kalin NH, Thurow ME, Rosenkranz MA, Davidson RJ (2003) Cortisol variation in humans affects memory for emotionally laden and neutral information. Behav Neurosci 117:505–516CrossRefPubMedGoogle Scholar
  2. Aerni A, Traber R, Hock C, Roozendaal B, Schelling G, Papassotiropoulos A et al (2004) Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry 161:1488–1490CrossRefPubMedGoogle Scholar
  3. Antypa N, van der Does AWJ, Smelt AHM, Rogers RD (2009) Omega-3 fatty acids (fish-oil) and depression-related cognition in healthy volunteers. J Psychopharmacol 23:831–840CrossRefPubMedGoogle Scholar
  4. Beaver JD, Lawrence AD, Passamonti L, Calder AJ (2008) Appetitive motivation predicts the neural response to facial signals of aggression. J Neurosci 28:2719–2725CrossRefPubMedGoogle Scholar
  5. Bechara A, Tranel D, Damasio H, Damasio AR (1996) Failure to respond autonomically to anticipated future outcomes following damage to prefrontal cortex. Cereb Cortex 6:215–225CrossRefPubMedGoogle Scholar
  6. Buchanan TW, Brechtel A, Sollers JJ, Lovallo WR (2001) Exogenous cortisol exerts effects on the startle reflex independent of emotional modulation. Pharmacol Biochem Behav 68:203–210CrossRefPubMedGoogle Scholar
  7. Carver CS, Harmon-Jones E (2009) Anger is an apppraoch-related affect: evidence and implications. Psycho Bull 135:183–204CrossRefGoogle Scholar
  8. d’Alfonso AA, van Honk J, Hermans E, Postma A, de Haan EH (2000) Laterality effects in selective attention to threat after repetitive transcranial magnetic stimulation at the prefrontal cortex in female subjects. Neurosci Lett 280:195–198CrossRefPubMedGoogle Scholar
  9. de Kloet ER, Oitzl MS, Joels M (1999) Stress and cognition: are corticosteroids good or bad guys? Tr Neurosci 22:422–426CrossRefGoogle Scholar
  10. de Kloet ER, Joels M, Holsboer F (2005) Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6:463–475CrossRefPubMedGoogle Scholar
  11. de Quervain DJF, Margraf J (2008) Glucocorticoids for the treatment of post-traumatic stress disorder and phobias: a novel therapeutic approach. Eur J Pharmacol 583:365–371CrossRefPubMedGoogle Scholar
  12. Etkin A, Egner T, Peraza DM, Kandel ER, Hirsch J (2006) Resolving emotional conflict: a role for the rostral anterior cingulate cortex in modulating activity in the amygdala. Neuron 51:871–882CrossRefPubMedGoogle Scholar
  13. Harmer CJ (2008) Serotonin and emotional processing: does it help explain antidepressant drug action? Neuropharmacol 55:1023–1028CrossRefGoogle Scholar
  14. Hermans E, Ramsey NF, van Honk J (2008) Exogenous testosterone enhances responsiveness to social threat in the neural circuitry of social aggression in humans. Biol Psychiatry 63:263–270CrossRefPubMedGoogle Scholar
  15. Het S, Wolf OT (2007) Mood changes in response to psychosocial stress in healthy young women: effects of pretreatment with cortisol. Behav Neurosci 121:11–20CrossRefPubMedGoogle Scholar
  16. Kizildere S, Glück T, Zietz B, Schölmerich J, Straub RH (2003) During a corticotropin-releasing hormone test in healthy subjects, administration of a beta-adrenergic antagonist induced secretion of cortisol and dehydroepiandrosterone sulfate and inhibited secretion of ACTH. Eur J Endocrinol 148:45–53CrossRefPubMedGoogle Scholar
  17. Koob G, Kreek MJ (2007) Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 164:1149–1159CrossRefPubMedGoogle Scholar
  18. Liberzon I, King AP, Britton JC, Phan KL, Abelson JL, Taylor SF (2007) Paralimbic and medial prefrontal cortical involvement in neuroendocrine responses to traumatic stimuli. Am J Psychiatry 164:1250–1258CrossRefPubMedGoogle Scholar
  19. Lupien SJ, Gillin CJ, Hauger RL (1999) Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose–response study in humans. Behav Neurosci 113:420–430CrossRefPubMedGoogle Scholar
  20. Mantella RC, Butters MA, Amico JA, Mazumdar S, Rollman BL, Begley AE et al (2008) Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinol 33:773–781CrossRefGoogle Scholar
  21. Mantsch JR, Katz ES (2007) Elevation of glucocorticoids is necessary but not sufficient for the escalation of cocaine self-administration by chronic electric footshock in rats. Neuropsychopharmacol 32:367–376CrossRefGoogle Scholar
  22. Marinelli M, Piazza PV (2002) Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur J NeuroSci 16:387–394CrossRefPubMedGoogle Scholar
  23. Marinelli M, Aouizerate B, Barrot M, Le MM, Piazza PV (1998) Dopamine dependent responses to morphine depend on glucocorticoid receptors. Proc Natl Acad Sci USA 95:7742–7747CrossRefPubMedGoogle Scholar
  24. Mikics E, Barsy B, Haller J (2007) The effect of glucocorticoids on aggressiveness in established colonies of rats. Psychoneuroendocrinol 32:160–170CrossRefGoogle Scholar
  25. Ochsner KN, Gross JJ (2005) The cognitive control of emotion. Tr Cogn Sci 9:242–249CrossRefGoogle Scholar
  26. Oei NYL, Tollenaar MS, Elzinga BM, Spinhoven P (2009) Hydrocortisone reduces emotional distracter interference in working memory. Psychoneuroendocrinol 34:1284–1293CrossRefGoogle Scholar
  27. Passamonti L, Rowe JB, Ewbank M, Hampshire A, Keane J, Calder AJ (2008) Connectivity from the ventral anterior cingulated to the amygdala is modulated by appetitive motivation in response to facial signals of aggression. Neuroimage 43:562–570CrossRefPubMedGoogle Scholar
  28. Putman P, Hermans E, van Honk J (2004) Emotional Stroop performance for masked angry faces: it’s BAS, not BIS. Emotion 4:305–311CrossRefPubMedGoogle Scholar
  29. Putman P, Hermans EJ, Koppeschaar H, Van Schijndel A, van Honk J (2007a) A single administration of cortisol acutely reduces preconscious attention for fear in anxious young men. Psychoneuroendocrinol 32:793–802CrossRefGoogle Scholar
  30. Putman P, Hermans EJ, van Honk J (2007b) Exogenous cortisol shifts a motivated bias from fear to anger in spatial working memory for facial expressions. Psychoneuroendocrinol 32:14–21CrossRefGoogle Scholar
  31. Putman P, Hermans EJ, van Honk, J (2009) Cortisol administration acutely reduces threat-selective spatial attention in healthy young men. Physiol Behav (in press)Google Scholar
  32. Rogers RD, Em T, Bhagwagar Z, Drevets WC, Sahakian BJ, Carter CS (2003) Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. Neuropsychopharmacol 32:417–428CrossRefGoogle Scholar
  33. Rogers RD, Lancaster M, Wakeley J, Bhagwagar Z (2004) Effects of beta-adrenoreceptor blockade on components of human decision-making. Psychopharmacol 172:157–164CrossRefGoogle Scholar
  34. Sapolsky Rm, Romero LM, Munck AU (2000) How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 21:55–89CrossRefPubMedGoogle Scholar
  35. Schelling G, Roozendaal B, Krauseneck T, Schmoelz M, de Quervain DJF, Briegel J (2006) Efficacy of hydrocortisone in preventing posttraumatic stress disorder following critical illness and major surgery. Ann NY Acad Sci 1071:46–53CrossRefPubMedGoogle Scholar
  36. Sinha R (2008) Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sc 1141:105–130CrossRefGoogle Scholar
  37. Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U et al (2006) Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA 103:5585–5590CrossRefPubMedGoogle Scholar
  38. Spielberger CD (1983) Manual for the State-Trait Anxiety Inventory (STAI-form Y). Consulting Psychologists Press, Palo AltoGoogle Scholar
  39. Strome EM, Wheler GH, Higley JD, Loriaux DL, Suomi SJ, Doudet DJ (2002) Intracerebroventricular corticotropin-releasing factor increases limbic glucose metabolism and has social context-dependent behavioral effects in nonhuman primates. Proc Natl Acad Sci USA 99:15749–15754CrossRefPubMedGoogle Scholar
  40. Takahashi T, Ikeda K, Ishikawa M, Kitamura N, Tsukasaki T, Nakama D et al (2005) Anxiety, reactivity, and social stress-induced cortisol elevation in humans. Neuro Endocrinol Lett 26:351–354PubMedGoogle Scholar
  41. Tops M, van der Pompe G, Baas D, Mulder LJ, Den Boer JA, Meijman TF, Korf J (2003) Acute cortisol effects on immediate free recall and recognition of nouns depend on stimulus valence. Psychophysiol 40:167–173CrossRefGoogle Scholar
  42. Tops M, Wijers AA, Koch T, Korf J (2006) Modulation of rotational behavior in healthy volunteers by cortisol administration. Biol Psychol 71:240–243CrossRefPubMedGoogle Scholar
  43. Urry HL, van Reekum CM, Johnstone T, Kalin NH, Thurow ME, Schaefer HS et al (2006) Amygdala and ventromedial prefrontal cortex are inversely coupled during regulation of negative affect and predict the diurnal pattern of cortisol secretion among older adults. J Neurosci 26:4415–4425CrossRefPubMedGoogle Scholar
  44. Van den Bos R, Harteveld M, Stoop H (2009) Stress and decision-making in humans: performance is related to cortisol reactivity, albeit differently in men and women. Psychoneurondocrinol 34:1449–1458CrossRefGoogle Scholar
  45. Van der Ploeg HM, Defares PB, Spielberger CD (1980) ZBV: handleiding bij de zelf-beoordelings vragenlijst: een Nederlandstalige bewerking van Spielberger state-trait anxiety inventory STAI-Y. Harcourt, AmsterdamGoogle Scholar
  46. van Honk J, Tuiten A, de Haan E, van der Hout M, Stam H (2001) Atttentional biases for angry faces: relationships to trait anger and anxiety. Cogn Emotion 15:279–297Google Scholar
  47. Van Honk J, Hermans EJ, Putman P, Montagne B, Schutter DJ (2002) Defective somatic markers in sub-clinical psychopathy. NeuroReport 13:1025–1027CrossRefPubMedGoogle Scholar
  48. Vasa RA, Pine DS, Masten CL, Vythillingam M, Collin C, Charney DS et al (2009) Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacol 204:445–455CrossRefGoogle Scholar
  49. Vreeburg SA, Hoogendijk WJ, van Pelt J, Derijk RH, Verhagen JC, van Dyck R et al (2009) Major depressive disorder and hypothalamic–pituitary–adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry 66:617–626CrossRefPubMedGoogle Scholar
  50. Wirth MM, Schultheiss OC (2007) Basal testosterone moderates responses to anger faces in humans. Physiol Behav 90:496–505CrossRefPubMedGoogle Scholar
  51. Wohl MJA, Matheson K, Young MM, Anisman H (2008) Cortisol rise following awakening among problem gamblers: dissociation from comorbid symptoms of depression and impulsivity. J Gambl Stud 24:79–90CrossRefPubMedGoogle Scholar
  52. Yehuda R (2001) Biology of posttraumatic stress disorder. J Clin Psychiatry 62(17):41–46PubMedGoogle Scholar
  53. Yehuda R (2004) Risk and resilience in posttraumatic stress disorder. J Clin Psychiatry 65:29–36PubMedGoogle Scholar
  54. Yehuda R, Teicher MH, Trestman RL, Levengood RA, Siever LJ (1996) Cortisol regulation in posttraumatic stress disorder and major depression: a chronobiological analysis. Biol Psychiatry 40:79–88CrossRefPubMedGoogle Scholar
  55. Young EA, Breslau N (2004) Cortisol and catecholamines in posttraumatic stress disorder: an epidemiologic community study. Arch Gen Psychiatry 61:394–401CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2009

Authors and Affiliations

  • Peter Putman
    • 1
    • 2
  • Niki Antypa
    • 1
  • Panagiota Crysovergi
    • 1
  • Willem A. J. van der Does
    • 1
  1. 1.Institute of PsychologyLeiden UniversityLeidenThe Netherlands
  2. 2.Clinical, Health, and NeuropsychologyLeiden UniversityLeidenThe Netherlands

Personalised recommendations